
The AHA today released a new report showing how the unlawful actions of drug companies to limit 340B pricing with community and specialty pharmacies are having an adverse impact on access to care for patients and communities across the country. The report is based on a survey of more than 300 hospitals and health systems participating in the 340B program conducted earlier this year by the AHA.